EcoDrugPlus

Beta-Secretase 1

Ensembl ID : ENSUAMG00000004571
Gene Symbol: BACE1
2 Cross references
217 Possible Orthologues:

Bradykinin Receptor B1

Ensembl ID : ENSUAMG00000019852
Gene Symbol: BDKRB1
2 Cross references
147 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSUAMG00000019853
Gene Symbol: BDKRB2
2 Cross references
356 Possible Orthologues:

Butyrylcholinesterase

Ensembl ID : ENSUAMG00000026761
Gene Symbol: BCHE
2 Cross references
130 Possible Orthologues:

Calcitonin Receptor Like Receptor

Ensembl ID : ENSUAMG00000021347
Gene Symbol: CALCRL
2 Cross references
147 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSUAMG00000027251
Gene Symbol: CASR
2 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSUAMG00000015744
Gene Symbol: CACNA2D3
2 Cross references
307 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSUAMG00000017546
Gene Symbol: CACNA2D4
2 Cross references
317 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 1

Ensembl ID : ENSUAMG00000012212
Gene Symbol: CACNB1
2 Cross references
209 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2

Ensembl ID : ENSUAMG00000004705
Gene Symbol: CACNB2
2 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSUAMG00000027084
Gene Symbol: CACNB3
2 Cross references
275 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 4

Ensembl ID : ENSUAMG00000002586
Gene Symbol: CACNB4
1 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).